Our Original Stem Cell Safety Paper has been Declared in the Top 1% of Papers in it’s Area

stem cell safety paper

Our original stem cell safety paper was just declared in the top 1% of the papers in it’s field. This means that it’s been cited by more than 20 other papers as research of authority. This is on the heels of it’s successor paper that again looked at stem cell safety in the same patients and the outcomes of knee stem cell injections being named the best of it’s kind in stem cell joint injection papers. We’re proud of our Regenexx Research team and want to note that these distinctions point to the time, effort, and energy we have placed on our research efforts. This is very rare in the stem cell field, where 99.99% of the practicing physicians aren’t performing or publishing any research.

Learn More About Regenexx® Procedures
Request a digital booklet and more information to learn about alternatives to orthopedic surgery and the Regenexx patient experience.
We do not sell, or share your information to third party vendors. By submitting the form you agree that you've read and consent to our Privacy Policy.
Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

TO TOP